Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 7, Issue 5, 2012, Pages 900-905

  Bölükbas, Servet ^a   Eberlein, Michael ^b   Schirren, Joachim ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Decortication; Mesothelioma; Perfusion; Pleurectomy; Pulmonary function

Indexed keywords

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; DIAPHRAGM; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG PERFUSION; LUNG SPARING RADICAL PLEURECTOMY; MALE; PLEURA MESOTHELIOMA; PLEURECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 84862125526     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824de2dc     Document Type: Article

References (26)

1. Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer 1975;35:734-738.
2. Bölükbas S, Manegold C, Eberlein M, et al. Trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/permetrexed and radiotherapy. Lung Cancer 2011;71:75-81.
3. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008; 34:886-891.
4. Gokce M, Okur E, Baysungur V, Ergene G, Sevilgen G, Halezeroglu S. Lung decortication for chronic empyaema: effects on pulmonary function and thoracic asymmetry in the late period. Eur J Cardiothorac Surg 2009;36:754-758.
5. Rzyman W, Skokowski J, Romanowicz G, et al. Decortication in chronic pleural empyema - effect on lung function. Eur J Cardiothorac Surg, 2002;21:502-507.
6. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
7. Rice D, Rusch V, Pass H, et al.; International Association for the Study of Lung Cancer International Staging Committee, and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011;6:1304-1312.
8. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010;5:1841-1848.
9. Sensakovic WF, Armato SG 3rd, Starkey A, Kindler HL, Vigneswaran WT. Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol 2011;18:294-298.
10. Fromageot C, Lofaso F, Annane D, et al. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders. Arch Phys Med Rehabil 2001;82:123-128.
11. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-338.
12. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-927.
13. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.
14. de Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2007;133:111-116.
15. Serke M, Bauer T. Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma. ASCO Meeting Abstracts 2007;25:18198.
16. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
17. Balduyck B, Hendriks J, Lauwers P, Sardari Nia P, Van Schil P. Quality of life evolution after lung cancer surgery in septuagenarians: a prospective study. Eur J Cardiothorac Surg 2009;35:1070-1075; discussion 1075.
18. Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L. Quality of life of long-term survivors of non-small-cell lung cancer. J Clin Oncol 2002;20:2920-2929.
19. Krug LM, Arduino JM, Sun X, et al. Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM). ASCO Meeting Abstracts 2011;29:7028.
20. Brunelli A, Socci L, Refai M, et al. Quality of life before and after major lung resection for lung cancer: a prospective follow-up analysis. Ann Thorac Surg 2007;84:410-416.
21. Flores RM, Alam NZ. Malignant pleural mesothelioma: patient selection for pleurectomy. In Ferguson MK (Ed.), Difficult Decisions in Thoracic Surgery, London: Springer, 2011, pp. 409-415.
22. Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor and mortality and morbidity after lung resection. Am Rev Respir Dis 1989;139:902-910.
23. Burney PG Hooper R. Forced vital capacity, airway obstruction and survival in a general population sample from the USA. Thorax 2011;66: 49-54.
24. Lee JH, Song EM, Sim YS, Ryu YJ, Chang JH. Forced expiratory volume in one second as a prognostic factor in advanced non-small cell lung cancer. J Thorac Oncol 2011;6:305-309.
25. Brunelli A, Charloux A, Bolliger CT, et al.; European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009;34:17-41.
26. Birim O, Maat AP, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003;23:30-34.